#	Pagina
attuale pagina	/open-h2020/projects/194714/index.html
-1	/open-h2020/projects/214100/index.html
-2	/open-h2020/projects/214497/index.html
-3	/open-h2020/projects/226661/index.html
-4	/open-h2020/projects/210174/deliverables.html
-5	/open-h2020/per-topic/biorefinary/list/index.html
-6	/open-h2020/per-topic/autopiloting/list/index.html
-7	/open-h2020/per-topic/terrestrial/list/index.html
-8	/open-h2020/per-topic/pusher/list/index.html
-9	/open-h2020/per-topic/palaeolandscape/list/index.html
-10	/open-h2020/per-topic/kenia/list/index.html

Opendata, web and dolomites

TISSUE

Tissue In Stroke Stratification Using e-ASPECTSTW

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TISSUE project word cloud

Explore the words cloud of the TISSUE project. It provides you a very rough idea of what is the project "TISSUE" about.

neurological acute receive market additional 275 version output profits projections standardised onset centre nccts patients 250 hospitals untreated stratification symptom 20 cerebrovascular economic device size commercial tissue eligible medical 325 computed indirect validate imaging prospective feasibility strategy financial business easily fast leaders accessible stroke revenues hours plan unknown burden ltd ncct arrive restricted budget model health socioeconomic treatment biomarkers automated euros tomography benefits hospital worldwide clinical employment trial benefit reaching participating disorders 000 ischaemic approved 25 intravenous pricing global biomarker contrast thrombolysis brainomix full time position software competition annual clinically direct scans units brain aspectstw

Project "TISSUE" data sheet

The following table provides information about the project.

Coordinator	BRAINOMIX LIMITED Organization address address: SUFFOLK HOUSE SUITES 11-14 263 BANBURY ROAD city: OXFORD postcode: OX2 7HN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2594-phc-12-2014.html
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2014
Duration (year-month-day)	from 2014-10-01 to 2015-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BRAINOMIX LIMITED BRAINOMIX LIMITED Organization address address: SUFFOLK HOUSE SUITES 11-14 263 BANBURY ROAD city: OXFORD postcode: OX2 7HN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	coordinator	50˙000.00

Map

Project objective

Stroke is a burden with far reaching socioeconomic impact. The only approved treatment in ischaemic stroke is intravenous thrombolysis, which is restricted to 4.5 hours after symptom onset and currently, only 20% of all stroke cases are eligible to receive it. An additional 25% remain untreated because they arrive at the hospital with unknown time of onset.

The objective of the “Tissue In Stroke Stratification Using e-ASPECTSTW” (TISSUE) proposal is to clinically validate the ASPECTS method and its automated version, the medical device software e-ASPECTSTW, as an imaging biomarker on Non-Contrast Computed Tomography (NCCT) brain scans for identifying ischaemic stroke patients with unknown time of onset who can benefit from thrombolysis.

e-ASPECTSTW addresses the growing worldwide market of 3,250,000 patients (275,000 patients in Europe) every year having a stroke with unknown time of onset. The annual global market size of e-ASPECTSTW is 325,000,000 Euros. Users of e-ASPECTSTW will be hospitals worldwide that provide acute stroke treatment. e-ASPECTSTW will be integrated in existing clinical pathways offering a standardised, fast, reliable and easily accessible assessment of NCCTs. This will increase the uptake of thrombolysis and provide significant economic benefits to hospitals and the health system. The commercial exploitation of the project results will enhance the growth of Brainomix Ltd leading to increased revenues, profits, employment and will position Brainomix as leaders in imaging biomarkers for neurological and cerebrovascular disorders.

The output of the feasibility study will be a full business plan, including an analysis of the European and global stroke market, an analysis of direct, indirect and potential competition; a detailed business model and pricing strategy as well as financial projections and a detailed design and budget of the prospective multi-centre clinical trial including the participating stroke units.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TISSUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TISSUE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination